Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab
The administration of anti-interleukin-5/receptor (IL-5/R) therapies, benralizumab and mepolizumab, enable discontinuation of OGCs in some patients with EGPA, while avoiding relapses. These findings suggest that adding anti-IL-5/R therapy to standard primary treatment for patients with EGPA may improve response.
Authors
- Ulrich Specks (ORCID: https://orcid.org/0000-0002-6559-1206)
- Sofia Necander
- Anat Shavit
- David R.W. Jayne (ORCID: https://orcid.org/0000-0002-1712-0637)
- Christian Pagnoux (ORCID: https://orcid.org/0000-0001-6287-9549)
- Lena Börjesson Sjö
- Nancy Agmon‐Levin (ORCID: https://orcid.org/0000-0001-9514-3677)
- Claire Walton
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- Michael E. Wechsler
Institutions
- AstraZeneca (United Kingdom) (GB)
- Mount Sinai Hospital (CA)
- Mayo Clinic (US)
- University of Cambridge (GB)
- Sheba Medical Center (IL)
- National Jewish Health (US)
- AstraZeneca (South Korea) (KR)
- Bridge University (SS)
- AstraZeneca (France) (FR)
- Mayo Clinic in Arizona (US)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Sweden) (SE)
- Mayo Clinic in Florida (US)
- AstraZeneca (Spain) (ES)
- University of Pennsylvania (US)
- University of Colorado Denver (US)
- Philadelphia University (US)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1002/acr2.70096
- Citations
- 2
- Primary Topic
- Eosinophilic Esophagitis
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- AstraZeneca